000 04002nam a22004815i 4500
001 vtls000544534
003 RU-ToGU
005 20210922083042.0
007 cr nn 008mamaa
008 160915s2014 gw | s |||| 0|eng d
020 _a9783642384042
_9978-3-642-38404-2
024 7 _a10.1007/978-3-642-38404-2
_2doi
035 _ato000544534
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aEpigenetic Therapy of Cancer
_helectronic resource
_bPreclinical Models and Treatment Approaches /
_cedited by Michael Lübbert, Peter A. Jones.
260 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2014.
300 _aX, 325 p. 48 illus., 14 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aThe fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation -- Mouse models to study DNA methylation in cancer research -- Epigenetic regulation of normal hematopoietic development -- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies -- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches -- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins -- Epigenetic abnormalities in lung cancer -- Pharmacodynamic Responses to DNA Methyltransferase Inhibition -- Histone Methyltransferases: Opportunities in Cancer Drug Discovery -- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy -- Clinical Implications of Epigenetic Alterations in Lung Cancer -- Epigenetic disturbances in colorectal cancer -- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.
520 _aThe growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
650 0 _amedicine.
_9566220
650 0 _aGene Therapy.
_9329107
650 0 _aHematology.
_9307898
650 0 _aOncology.
_9303086
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aOncology.
_9303086
650 2 4 _aHematology.
_9307898
650 2 4 _aGene Therapy.
_9329107
700 1 _aLübbert, Michael.
_eeditor.
_9452263
700 1 _aJones, Peter A.
_eeditor.
_9452264
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-38404-2
912 _aZDB-2-SME
999 _c402321